Clinical trial readout dates for Arcus Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2028.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 Domvanalimab Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer · NCT04736173 | September 2026 Primary data collected |
| Phase 2 Domvanalimab Gastrointestinal Tract Malignancies · NCT05329766 | September 2026 Primary data collected |
| Phase 3 Domvanalimab Advanced Upper Gastrointestinal Tract Adenocarcinoma · NCT05568095 | August 2026 Primary data collected |
| Phase 3 Casdatifan Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma · NCT07011719 | April 2028 Recruiting |
| Phase 3 Quemliclustat Metastatic Pancreatic Ductal Adenocarcinoma · NCT06608927 | November 2030 Ongoing |
Arcus Biosciences Inc. reported $845M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $128M; at that rate the cash would last about 7 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |
| 8-K Other Events — often topline trial data | 2026-10-23 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-21 |
| 8-K Other Events — often topline trial data | 2026-10-20 |